HC Wainwright & Co. Reiterates Buy on Madrigal Pharmaceuticals, Maintains $225 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and maintained a price target of $225.
September 14, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $225.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Madrigal Pharmaceuticals. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100